This is a market research notice for a potential five-year IDIQ contract with the FDA to supply a wide variety of brand name and generic pharmaceuticals, including small molecule and peptide therapeutics, for research purposes. The contract has a guaranteed minimum of $10,000 and an estimated maximum value of $4,000,000 over its term. Services involve delivering pharmaceutical products to various FDA offices, laboratories, and external research collaborators located both within the United States and internationally. The performance timeline is for five one-year ordering periods, estimated to run from August 1, 2026, through July 31, 2031. The FDA is specifically seeking small business sources for this requirement but encourages capability statements from all interested parties.